Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
Submitted by
admin
on December 1, 2023 - 9:43am
Source:
Medical Marketing and Media
News Tags:
biotech stocks
AbbVie
Immunogen
M&A
Headline:
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
snippet:
Biotech stocks rose as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10 billion.
Shares of ImmunoGen, which develops cancer treatments called antibody-drug conjugates, closed nearly 83% higher.
Other biotech companies developing ADCs jumped on the news of the buyout.
Do Not Allow Advertisers to Use My Personal information
